---
title: "RBC Capital Keeps Their Hold Rating on ADC Therapeutics (ADCT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292133790.md"
description: "RBC Capital analyst Leonid Timashev maintained a Hold rating on ADC Therapeutics (ADCT) with a $2.00 price target, as reported on July 7. The stock closed at $1.35. Timashev, a 5-star analyst in the Healthcare sector, contrasts with the broader TipRanks consensus of Moderate Buy and a higher average price target of $5.67."
datetime: "2026-07-09T01:46:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292133790.md)
  - [en](https://longbridge.com/en/news/292133790.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292133790.md)
---

# RBC Capital Keeps Their Hold Rating on ADC Therapeutics (ADCT)

In a report released on July 7, Leonid Timashev from RBC Capital maintained a Hold rating on ADC Therapeutics, with a price target of $2.00. The company’s shares closed yesterday at $1.35.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Timashev is a 5-star analyst with an average return of 27.7% and a 61.41% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Insmed, Revolution Medicines, and ADC Therapeutics.

ADC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.67.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL](https://longbridge.com/en/news/291272696.md)
- [ADC Therapeutics reports positive LOTIS-5 PFS results; plans pre-sBLA meeting and Q4 2026 sBLA](https://longbridge.com/en/news/288624565.md)
- [Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk Therapeutics](https://longbridge.com/en/news/293474953.md)
- [Sensorion SAS (RFM) Receives a New Rating from Chardan Capital](https://longbridge.com/en/news/293386223.md)
- [Thermo Fisher Rated Buy on Broad-Based Recovery, Conservative Guidance, and Attractive Valuation Versus Peers](https://longbridge.com/en/news/293715975.md)